8-K: cbdMD Secures $1.7M in Preferred Stock Offering

cbdMD, Inc. has raised $1.7 million through the issuance of Series B Convertible Preferred Stock to institutional investors, bolstering its working capital.

Summary

• cbdMD, Inc. (YCBD) completed a private placement of Series B Convertible Preferred Stock to four institutional investors.
• The company issued 1,700,000 shares of Series B Preferred Stock for aggregate gross proceeds of $1,700,000.
• Net proceeds to the company were $1,500,000, designated for working capital purposes.
• Each share of Series B Preferred Stock is convertible into common stock at a conversion price of $1.00, subject to anti-dilution adjustments.
• Dividends accrue at 10% per annum, payable quarterly in common stock (if Equity Conditions are met) or cash.
• The Series B Preferred Stock ranks senior to common stock in liquidation and has no general voting rights, except on matters affecting its preferences.
• A Registration Rights Agreement requires cbdMD to file an S-1 registration statement within 30 days to register the underlying common shares for resale.
• The transaction was exempt from registration under Section 4(a)(2) and Rule 506(b).
• A beneficial ownership limitation restricts conversion if a holder would own more than 4.99% of outstanding common stock, adjustable to 9.99% with notice.
• An Exchange Cap limits conversions to 19.99% of pre-agreement outstanding common stock until stockholder approval is obtained.

Sentiment

Score: 6

Explanation: The capital raise provides essential working capital, which is a positive for the company's immediate operational stability. However, the high dividend rate and potential for significant dilution from the convertible preferred stock, coupled with the company's existing financial challenges (implied by the need for this type of financing and the NYSE American listing standards reference), temper the overall positive sentiment. The MFN clause and restrictions on future financings also add complexity.

Positives

• Successfully raised $1.7 million in gross proceeds ($1.5 million net) to enhance working capital.
• Secured funding from institutional investors, indicating some level of investor confidence.
• The Series B Preferred Stock has a liquidation preference, ranking senior to common stock.
• The company is required to register the underlying common shares, providing a path to liquidity for investors.

Negatives

• The issuance of convertible preferred stock and potential conversion into common stock will be dilutive to existing common shareholders.
• Dividends are 10% per annum, which is a significant cost of capital, and can be paid in common stock, leading to further dilution.
• The beneficial ownership limitation and Exchange Cap could restrict investors' ability to convert and sell shares, potentially impacting liquidity for the preferred shareholders.
• The MFN clause means the company cannot offer more favorable terms to future investors without extending them to current Series B holders, potentially limiting future financing flexibility.

Risks

• Dilution Risk: Conversion of Series B Preferred Stock into common stock will increase the number of outstanding common shares, diluting the ownership and voting power of existing common stockholders.
• Liquidity Risk for Investors: The beneficial ownership limitation (4.99%, adjustable to 9.99%) and the Exchange Cap (19.99% of pre-agreement outstanding common stock until stockholder approval) may restrict the ability of Series B holders to convert and sell their shares.
• Operational Risks (Triggering Events): Various events, including failure to maintain registration statement effectiveness, trading suspensions, conversion/delivery failures, insufficient authorized shares, failure to pay dividends, default on $1M+ indebtedness, bankruptcy, or a Material Adverse Effect, could trigger adverse consequences for the company and preferred shareholders.
• Financial Covenants Risk: The company is subject to covenants regarding indebtedness, liens, restricted payments, asset transfers, and maintaining corporate existence, with breaches potentially leading to Triggering Events.
• Market Price Volatility: The conversion price adjustments and dividend calculations are tied to the common stock's market price (VWAP), exposing investors to market volatility.
• Future Financing Constraints: The MFN clause and restrictions on 'Subsequent Placements' (for 90 business days after the 'Applicable Date') could limit the company's flexibility in raising future capital on potentially more favorable terms.

Future Outlook

The company will use the net proceeds from this offering for general working capital purposes. It is obligated to file a registration statement for the resale of the underlying common stock within 30 days and may need to seek stockholder approval to waive certain conversion limitations (Exchange Cap) in the future.

Management Comments

• Net proceeds of $1,500,000 shall be used for working capital purposes.
• The company and its board of directors have taken all necessary action to render inapplicable any control share acquisition, interested stockholder, business combination, poison pill, or other similar anti-takeover provision.
• The company acknowledges that its obligation to issue Conversion Shares is absolute and unconditional, regardless of the dilutive effect on other stockholders.

Industry Context

This capital raise provides cbdMD with additional liquidity, which is crucial for companies in the evolving and often capital-intensive CBD and wellness industry. The terms, particularly the high dividend rate and anti-dilution provisions, reflect the perceived risk or current financial standing of the company within its sector. The need for working capital suggests ongoing operational needs or strategic initiatives.

Comparison to Industry Standards

• The 10% annual dividend rate on preferred stock is relatively high, suggesting a higher risk profile or a need to attract capital in a challenging market compared to more established companies with lower cost of capital.
• The conversion price of $1.00, subject to anti-dilution, provides downside protection for investors, which is common in private placements for growth-stage or higher-risk companies.
• The beneficial ownership limitation (4.99%) and Exchange Cap (19.99%) are standard provisions to avoid triggering certain regulatory or exchange rules (e.g., NYSE American listing rules) that require shareholder approval for significant equity issuances.
• The MFN clause is a common investor protection in private placements, ensuring that early investors are not disadvantaged by more favorable terms offered in subsequent financings.

Corporate Governance

Stakeholder Impact

• Shareholders (Common Stock): Will experience dilution from the issuance of Series B Preferred Stock and potential future conversions. Their voting power may be diluted. The high dividend rate on preferred stock could impact future earnings available for common shareholders.
• Investors (Series B Preferred Stock): Receive a 10% annual dividend and a liquidation preference, offering a degree of protection and income. They also gain registration rights for liquidity. However, conversion limitations (beneficial ownership, Exchange Cap) could affect their ability to fully realize their investment quickly.
• Company: Gains $1.5 million in net working capital, which is critical for operations and strategic initiatives. However, it incurs a significant cost of capital (10% dividend) and takes on obligations related to registration and anti-dilution.

Next Steps

• Company to file an initial Registration Statement on Form S-1 within 30 calendar days after the Execution Date (September 29, 2025) to cover the resale of Registrable Securities.
• Company to use commercially reasonable efforts to keep the Registration Statement effective until all Registrable Securities are resold.
• Company to potentially hold a meeting of stockholders to approve an increase in authorized common stock and waive the Exchange Cap if conversion limitations are met.

Key Dates

Recommendation

The capital raise provides essential working capital, which is a positive for the company's immediate operational stability. However, the terms of the preferred stock, including the high 10% dividend rate and the potential for significant dilution upon conversion, suggest a high cost of capital and underlying financial challenges. The company's reference to regaining and maintaining compliance with NYSE American listing standards further indicates a precarious position. While the funding is a necessary step, the dilutive nature and ongoing obligations create headwinds for common shareholders. A 'hold' recommendation is appropriate as the company navigates these challenges, with investors needing to monitor execution of the business plan and the impact of future dilution.

Keywords

cbdMD, YCBD, Series B Preferred Stock, Convertible Preferred Stock, Capital Raise, SEC Filing, 8-K, Registration Rights, Dilution, Working Capital, Institutional Investors, Corporate Finance, Equity Financing